Newsroom | 97200 results

IRVINE, Calif.--(BUSINESS WIRE)--Johnson & Johnson announced 12-month pilot-phase data from the OMNY-AF study and highlighted new findings related to the VARIPULSE Platform....

ST. LOUIS--(BUSINESS WIRE)--Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued a Final Written Decision following inter partes review (IPR), finding all 10 challenged claims of Exact Sciences’ U.S. Patent No. 11,970,746 (the ’746 patent) unpatentable. This decision follows the PTAB’s July 2025 Final Written...

PROVO, Utah--(BUSINESS WIRE)--Nu Skin Enterprises Inc. (NYSE: NUS) today announced the relaunch of “The Aging Myth: Unlocking the Mysteries of Looking and Feeling Young,” the updated edition of the bestselling book from Dr. Joseph Chang, chair of Nu Skin’s Scientific Advisory Board. The relaunch marks a significant milestone in the evolution of evidence-based beauty and wellness, bringing together decades of research that underpin Nu Skin’s science-led innovations — from ageLOC® technology to t...

FT. LAUDERDALE, Fla.--(BUSINESS WIRE)--Trividia Health, Inc., announced today that it is initiating a labeling correction which requires a modification of the Owner’s Booklets/System Instructions for Use for all TRUE METRIX, TRUE METRIX AIR, TRUE METRIX GO, and TRUE METRIX PRO Blood Glucose Monitoring Systems (collectively, the “Products”) distributed in the United States, United Kingdom, Mexico, Australia, and the Caribbean. Trividia is updating the E-5 Error Code in the “Messages” section of...

ウィスコンシン州マディソン--(BUSINESS WIRE)--（ビジネスワイヤ） -- 中国国家薬品監督管理局（NMPA）は、中国において、OncoMate® マイクロサテライト不安定性（MSI）検出キットを第III類の体外診断用医療機器として承認しました。本製品は、メルク・アンド・カンパニー（米国ニュージャージー州ローウェイ）の抗PD-1抗体療法であるKEYTRUDA®（ペムブロリズマブ）治療の対象となる、MSI-High（MSI-H）の固形がん患者を特定するためのコンパニオン診断薬としての使用を目的としています。また、プロメガのコンパニオン診断薬として初めてNMPAの承認を取得しました。 「今回の承認は、中国における、より個別化された効果的ながん治療の実現に向けた一歩となります」と、プロメガのグローバル臨床マーケット・ディレクターであるアロク・シャルマは述べています。「当社は、革新的な技術や人命を救う効果的な治療法へのアクセス拡大につながる世界的なソリューションを提供するために、製薬企業と協業できることを誇りに思います。」 中国では、依然として世界でも特に高いがん負担に直面して...

MADISON, Wisconsin, USA--(BUSINESS WIRE)--Chinas nationale Aufsichtsbehörde für Medizinprodukte, NMPA (National Medical Products Administration), hat das OncoMate® -Kit zum Nachweis von Mikrosatelliteninstabilität (MSI) als In-vitro-Diagnostikum der Klasse III in China zugelassen. Das Kit soll als Begleitdiagnostikum zur Identifizierung von hochgradiger Mikrosatelliteninstabilität (MSI-H) bei Patienten mit soliden Tumoren für die Behandlung mit KEYTRUDA® (Pembrolizumab) dienen, einer Anti-PD-1-...

LOS ANGELES--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call on Wednesday, March 4, 2026, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and fiscal year 2025, which ended December 31, 2025. The financial results will be reported in a press release after the close of regular stock market trading hours on Wed...

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) approved an update to the Yescarta® (axicabtagene ciloleucel) prescribing information removing the previous Limitations of Use in patients with relapsed or refractory (R/R) primary central nervous system lymphoma (PCNSL). The updated label reinforces the robust safety data of Yescarta in eligible patients with R/R PCNSL; Yescarta is the only CAR T-cell therap...

TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (TSX: MSCL, Nasdaq: MSLE) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced the pricing of its previously announced public offering (the “Offering”) of 4,455,445 common shares and, in lieu of common shares for certain investors, pre-funded warrants to purchase 495,049 common shares. The common shares are being sold at a price of US$10....

BOSTON--(BUSINESS WIRE)--Atrandi Biosciences announced it will present new scientific data and platform innovations at the SLAS2026 International Conference and Exhibition...